Newsroom
Portola in the News
2011
November 22
Portola Ready to Fly Solo on Pivotal Betrixaban Trial
BioWorld Today
By Mari Serebrov
Having raised $89 million in its latest financing round, Portola Pharmaceuticals Inc. is preparing to fly solo on its pivotal Phase III trial that will evaluate betrixaban in the prevention of pulmonary embolisms. More
BioWorld Today
By Mari Serebrov
Having raised $89 million in its latest financing round, Portola Pharmaceuticals Inc. is preparing to fly solo on its pivotal Phase III trial that will evaluate betrixaban in the prevention of pulmonary embolisms. More
November 7
Strategy: Biogen picks Syk
BioCentury
By Michael Flanagan
In its first significant deal since naming new heads of BD and R&D, Biogen Idec Inc. licensed a SYK inhibitor from Portola Pharmaceuticals Inc. that it hopes will overtake the first movers among oral rheumatoid arthritis products by offering better tolerability and more convenient dosing. PRT062607 will begin Phase IIa testing for RA in 2H12. More
BioCentury
By Michael Flanagan
In its first significant deal since naming new heads of BD and R&D, Biogen Idec Inc. licensed a SYK inhibitor from Portola Pharmaceuticals Inc. that it hopes will overtake the first movers among oral rheumatoid arthritis products by offering better tolerability and more convenient dosing. PRT062607 will begin Phase IIa testing for RA in 2H12. More
October 28
Portola Pharma Strikes $554M Deal With Biogen For Phase III Study
Dow Jones Venture Wire
By Brian Gormley
Portola Pharmaceuticals Inc. has struck a deal worth up to $553.5 million with Biogen Idec Inc. to help fund its plan to push its lead anticoagulant drug into a Phase III study of over 5,000 people next year. More
Dow Jones Venture Wire
By Brian Gormley
Portola Pharmaceuticals Inc. has struck a deal worth up to $553.5 million with Biogen Idec Inc. to help fund its plan to push its lead anticoagulant drug into a Phase III study of over 5,000 people next year. More
October 28
$45M Up Front, Potential $508.5M in Milestones:
Portola Lands Syk Inhibitor Deal with Biogen Idec
BioWorld Today
By Marie Powers
Fresh off a big score at the Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis conference in Amsterdam, the Netherlands, for its oral multiple sclerosis immune modulator BG-12, Biogen Idec has inked a multi-milliondollar deal with privately held Portola Pharmaceuticals Inc. More
BioWorld Today
By Marie Powers
Fresh off a big score at the Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis conference in Amsterdam, the Netherlands, for its oral multiple sclerosis immune modulator BG-12, Biogen Idec has inked a multi-milliondollar deal with privately held Portola Pharmaceuticals Inc. More
March 25
Portola Ready to Go it Alone After Merck Bows Out of Factor Xa Partnership
Scrip
By Donna Young
Portola Pharmaceuticals CEO William Lis said Merck's decision to return the rights to his firm for betrixaban, an investigational oral factor Xa inhibitor anticoagulant being evaluated for the prevention of stroke in patients with atrial fibrillation, came as no surprise, insisting that the companies had been in discussions for awhile about the smaller biotech independently taking the drug forward. More
Scrip
By Donna Young
Portola Pharmaceuticals CEO William Lis said Merck's decision to return the rights to his firm for betrixaban, an investigational oral factor Xa inhibitor anticoagulant being evaluated for the prevention of stroke in patients with atrial fibrillation, came as no surprise, insisting that the companies had been in discussions for awhile about the smaller biotech independently taking the drug forward. More
January 28
Portola Drug Targets Market of $2 Billion
San Francisco Business Times
By Ron Leuty
Big-money partnerships are turning into Portola Pharmaceuticals Inc.’s antidote to rough times in the biotech industry.
San Francisco Business Times
By Ron Leuty
Big-money partnerships are turning into Portola Pharmaceuticals Inc.’s antidote to rough times in the biotech industry.
The South San Francisco drug developer, which nearly two years ago inked deals with Merck & Co. and Novartis AG, expects to file an investigational new drug application this year for a recombinant protein that would quickly reverse the effects of blood thinners. More